Application of a commensal gut bacterium for the controlled delivery of heterologous proteins to the lower GI tract

口服给药是将治疗性蛋白质输送到肠道的首选途径。为了有效，必须克服重大障碍，包括最大限度地减少运输过程中的活动损失和控制所提供的剂量。我们的技术旨在克服这些障碍，并使用人类共生肠道细菌卵形杆菌(Bo)在肠道内输送治疗剂，以回应以膳食植物为基础的糖-木聚糖。这一药物传递平台技术将利用一种典型的Bo菌株进一步开发，该菌株产生一种有效治疗和预防肠道炎症的有效抗炎剂。确定最佳的剂量和给药方案，以及Bo和木聚糖剂量对肠道细菌的影响，并展示大肠的功能将实现这一目标。最终的成果将是一种具有强健特征的输送技术，具有临床前的安全性和治疗蛋白输送功能的证明

Oral administration is the preferred route for delivering therapeutic proteins to the gut. To be effective, significant obstacles including minimising loss of activity during transit and controlling the dose delivered must be overcome. Our technology is designed to overcome these obstacles and uses the human commensal gut bacterium, Bacteroides ovatus (Bo) to deliver therapeutic agents in the gut in response to the dietary plant based sugar, xylan. This drug delivery platform technology will be further developed using a characterised model Bo strain producing a potent anti-inflammatory agent that can effectively treat and prevent gut inflammation. Determining optimal dosing and delivery regimens and the impact of Bo and xylan dosing on resident gut bacteria and demonstrating functionality in the large bowel will achieve this. The final output will be a robustly characterised delivery technology with pre-clinical proof of safety and functionality for the delivery of therapeutic proteins